Does TRT actually hurt your heart? What the studies say

What's this video probably claiming?

Given the caption and the creator's history of sex ed and hormone content, this video is almost certainly walking through whether testosterone replacement therapy is safe for the heart. The framing is likely reassuring, probably leaning on the 2023 TRAVERSE trial as vindication that TRT doesn't cause heart attacks. That's a defensible position, but it's also incomplete in ways that matter. Creators responding to audience questions about TRT tend to compress nuance. The likely talking points: TRT got a bad rap from a flawed 2010 study, the big randomized trial cleared it, and men with low testosterone should feel safe going on treatment. Some of that is accurate. Some of it flattens real clinical complexity that a 47,000-view audience deserves to hear in full.

What does the science actually show?

The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) is the headline. It randomized 5,246 men aged 45-80 with hypogonadism and cardiovascular risk to testosterone or placebo and followed them for a median of 33 months. Major adverse cardiovascular events were not significantly higher in the testosterone group: 7.0% versus 7.3% in placebo. That is genuinely reassuring. However, the trial also found higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury in the TRT group. These findings are statistically significant and clinically relevant. They do not make TRT dangerous for most men, but they do mean the cardiovascular story is not simply resolved. Older data, including Basaria et al. (2010, NEJM) and Finkle et al. (2014, PLOS ONE), raised red flags that the field spent a decade arguing about. TRAVERSE mostly settled the MACE question. It did not settle everything.

Where does the social media noise diverge from clinical reality?

The most common mistake in TRT content is treating TRAVERSE as a blanket cardiovascular clearance. It isn't. The trial studied men on doses targeting testosterone levels of 350-750 ng/dL, within physiological range. Men who are using supraphysiologic doses, a common pattern in fitness and optimization communities, were not represented. Polycythemia (elevated red blood cell mass) is a known, dose-dependent risk of testosterone that increases clotting risk. TRAVERSE participants were monitored closely for hematocrit. Real-world users often are not. Additionally, the atrial fibrillation signal is not trivial for men over 45. Content that says TRT is heart-safe without addressing AF risk, polycythemia management, or the dose context of the evidence is not lying, but it is leaving out the part that changes clinical decisions for a meaningful subset of patients.

What should you actually know?

If you have diagnosed hypogonadism and cardiovascular risk factors, the best available evidence suggests TRT at physiological doses does not meaningfully increase your risk of heart attack or stroke. That is a real, hard-won finding from a well-designed randomized trial. It took 30 months and 5,000 patients to get there. What the evidence does not support is dismissing cardiovascular monitoring as unnecessary once you start. Hematocrit should be checked periodically. Atrial fibrillation symptoms are worth reporting. Men with a prior history of venous thromboembolism are a different risk category entirely. And anyone using testosterone outside of a monitored clinical relationship, whether through unregulated sources or self-titrated doses, is operating in an evidence vacuum. The TRAVERSE data does not apply to them. Work with a licensed clinician who actually reviews your labs.